207 related articles for article (PubMed ID: 30913226)
1. A non-randomized trial to assess the safety, tolerability, and pharmacokinetics of posaconazole oral suspension in immunocompromised children with neutropenia.
Arrieta AC; Sung L; Bradley JS; Zwaan CM; Gates D; Waskin H; Carmelitano P; Groll AH; Lehrnbecher T; Mangin E; Joshi A; Kartsonis NA; Walsh TJ; Paschke A
PLoS One; 2019; 14(3):e0212837. PubMed ID: 30913226
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics and safety of posaconazole intravenous solution and powder for oral suspension in children with neutropenia: an open-label, sequential dose-escalation trial.
Groll AH; Abdel-Azim H; Lehrnbecher T; Steinbach WJ; Paschke A; Mangin E; Winchell GA; Waskin H; Bruno CJ
Int J Antimicrob Agents; 2020 Sep; 56(3):106084. PubMed ID: 32682946
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics and safety results from the Phase 3 randomized, open-label, study of intravenous posaconazole in patients at risk of invasive fungal disease.
Cornely OA; Robertson MN; Haider S; Grigg A; Geddes M; Aoun M; Heinz WJ; Raad I; Schanz U; Meyer RG; Hammond SP; Mullane KM; Ostermann H; Ullmann AJ; Zimmerli S; Van Iersel MLPS; Hepler DA; Waskin H; Kartsonis NA; Maertens J
J Antimicrob Chemother; 2017 Dec; 72(12):3406-3413. PubMed ID: 28961714
[TBL] [Abstract][Full Text] [Related]
4. Phase 3 pharmacokinetics and safety study of a posaconazole tablet formulation in patients at risk for invasive fungal disease.
Cornely OA; Duarte RF; Haider S; Chandrasekar P; Helfgott D; Jiménez JL; Candoni A; Raad I; Laverdiere M; Langston A; Kartsonis N; Van Iersel M; Connelly N; Waskin H
J Antimicrob Chemother; 2016 Mar; 71(3):718-26. PubMed ID: 26612870
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics and Safety of Posaconazole Tablet Formulation in Chinese Participants at High Risk for Invasive Fungal Infection.
Liu K; Wu D; Li J; Chen H; Ning H; Zhao T; Dai H; Chen L; Mangin E; Winchell GA; Waskin H; Jiang J; Qiu Y; Zhao XM
Adv Ther; 2020 May; 37(5):2493-2506. PubMed ID: 32319040
[TBL] [Abstract][Full Text] [Related]
6. Phase 1b/3 Pharmacokinetics and Safety Study of Intravenous Posaconazole in Adult Asian Participants at High Risk for Invasive Fungal Infections.
Wu D; Mi Y; Weng J; Zhuang J; Ke X; Wang C; Liu K; Martinho M; Winchell GA; Zang Y; Xu L
Adv Ther; 2022 Apr; 39(4):1697-1710. PubMed ID: 35167031
[TBL] [Abstract][Full Text] [Related]
7. Phase 1B study of the pharmacokinetics and safety of posaconazole intravenous solution in patients at risk for invasive fungal disease.
Maertens J; Cornely OA; Ullmann AJ; Heinz WJ; Krishna G; Patino H; Caceres M; Kartsonis N; Waskin H; Robertson MN
Antimicrob Agents Chemother; 2014 Jul; 58(7):3610-7. PubMed ID: 24733463
[TBL] [Abstract][Full Text] [Related]
8. A Population Pharmacokinetic Modeling and Simulation Study of Posaconazole Oral Suspension in Immunocompromised Pediatric Patients: A Short Communication.
Elkayal O; Spriet I; Uyttebroeck A; Colita A; Annaert P; Allegaert K; Smits A; Van Daele R; Dreesen E
Ther Drug Monit; 2021 Aug; 43(4):512-518. PubMed ID: 33560094
[TBL] [Abstract][Full Text] [Related]
9. Posaconazole plasma concentrations in pediatric patients receiving antifungal prophylaxis during neutropenia.
Döring M; Cabanillas Stanchi KM; Klinker H; Eikemeier M; Feucht J; Blaeschke F; Schwarze CP; Ebinger M; Feuchtinger T; Handgretinger R; Heinz WJ
Med Mycol; 2017 Jun; 55(4):375-384. PubMed ID: 27703016
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics of Posaconazole Oral Suspension in Children Dosed According to Body Surface Area.
Vanstraelen K; Colita A; Bica AM; Mols R; Augustijns P; Peersman N; Vermeersch P; Annaert P; Spriet I
Pediatr Infect Dis J; 2016 Feb; 35(2):183-8. PubMed ID: 26544987
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics of oral posaconazole in neutropenic patients receiving chemotherapy for acute myelogenous leukemia or myelodysplastic syndrome.
Krishna G; AbuTarif M; Xuan F; Martinho M; Angulo D; Cornely OA
Pharmacotherapy; 2008 Oct; 28(10):1223-32. PubMed ID: 18823218
[TBL] [Abstract][Full Text] [Related]
12. Single-dose phase I study to evaluate the pharmacokinetics of posaconazole in new tablet and capsule formulations relative to oral suspension.
Krishna G; Ma L; Martinho M; O'Mara E
Antimicrob Agents Chemother; 2012 Aug; 56(8):4196-201. PubMed ID: 22615291
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics of different dosing strategies of oral posaconazole in patients with compromised gastrointestinal function and who are at high risk for invasive fungal infection.
Cornely OA; Helfgott D; Langston A; Heinz W; Vehreschild JJ; Vehreschild MJ; Krishna G; Ma L; Huyck S; McCarthy MC
Antimicrob Agents Chemother; 2012 May; 56(5):2652-8. PubMed ID: 22290953
[TBL] [Abstract][Full Text] [Related]
14. Posaconazole in immunocompromised pediatric patients.
Vicenzi EB; Cesaro S
Expert Rev Anti Infect Ther; 2018 Jul; 16(7):543-553. PubMed ID: 29912581
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics and safety of oral posaconazole in neutropenic stem cell transplant recipients.
Gubbins PO; Krishna G; Sansone-Parsons A; Penzak SR; Dong L; Martinho M; Anaissie EJ
Antimicrob Agents Chemother; 2006 Jun; 50(6):1993-9. PubMed ID: 16723557
[TBL] [Abstract][Full Text] [Related]
16. Posaconazole liquid vs tablet formulation in lung transplant recipients.
Stelzer D; Weber A; Ihle F; Matthes S; Ceelen F; Zimmermann G; Kneidinger N; Schramm R; Winter H; Zoller M; Vogeser M; Behr J; Neurohr C
Mycoses; 2018 Mar; 61(3):186-194. PubMed ID: 29110351
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics and safety of voriconazole following intravenous- to oral-dose escalation regimens.
Purkins L; Wood N; Ghahramani P; Greenhalgh K; Allen MJ; Kleinermans D
Antimicrob Agents Chemother; 2002 Aug; 46(8):2546-53. PubMed ID: 12121931
[TBL] [Abstract][Full Text] [Related]
18. Exposure-response of posaconazole used for prophylaxis against invasive fungal infections: evaluating the need to adjust doses based on drug concentrations in plasma.
Jang SH; Colangelo PM; Gobburu JV
Clin Pharmacol Ther; 2010 Jul; 88(1):115-9. PubMed ID: 20505665
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of the pharmacokinetics of posaconazole and rifabutin following co-administration to healthy men.
Krishna G; Parsons A; Kantesaria B; Mant T
Curr Med Res Opin; 2007 Mar; 23(3):545-52. PubMed ID: 17355736
[TBL] [Abstract][Full Text] [Related]
20. Efficacy, safety and feasibility of antifungal prophylaxis with posaconazole tablet in paediatric patients after haematopoietic stem cell transplantation.
Döring M; Cabanillas Stanchi KM; Queudeville M; Feucht J; Blaeschke F; Schlegel P; Feuchtinger T; Lang P; Müller I; Handgretinger R; Heinz WJ
J Cancer Res Clin Oncol; 2017 Jul; 143(7):1281-1292. PubMed ID: 28258343
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]